Compare PNRG & EIKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNRG | EIKN |
|---|---|---|
| Founded | 1973 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 348.9M | 316.3M |
| IPO Year | 1995 | 2026 |
| Metric | PNRG | EIKN |
|---|---|---|
| Price | $193.45 | $5.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 24.0K | ★ 535.4K |
| Earning Date | 11-27-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.57 | N/A |
| Revenue | ★ $189,052,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $42.03 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $133.40 | $5.01 |
| 52 Week High | $278.90 | $16.50 |
| Indicator | PNRG | EIKN |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 42.37 |
| Support Level | $194.74 | $5.01 |
| Resistance Level | $200.02 | $8.48 |
| Average True Range (ATR) | 8.22 | 0.60 |
| MACD | -1.58 | 0.11 |
| Stochastic Oscillator | 29.89 | 51.80 |
PrimeEnergy Resources Corp is an independent oil and natural gas company that is engaged in acquiring, developing, and producing oil and natural gas. It owns producing and non-producing properties located in Texas and Oklahoma. The company's business activities include development and exploratory drilling and providing well servicing support operations for many of the onshore oil and gas wells through its subsidiaries. It is also active in the acquisition of producing oil and gas properties through joint ventures with industry partners.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.